Endoscopic vacuum therapy for the management of gastro-esophageal perforations
Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S470
DOI: 10.1055/s-0044-1783891 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von R. Valente und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
Esophageal or gastric perforation is associated with systemic inflammatory response syndrome (SIRS), which can lead to multi-organ dysfunction and mortality in up to 50% of cases. Endoscopic vacuum therapy involves the use of a catheter with a sponge attached to its distal end, connected to a machine that applies negative pressure, allowing for continuous drainage of the perforation site and potentially promoting healing of the transmural defect. Previous series have reported promising results, indicating the potential effectiveness of this therapy in managing esophageal perforations. To evaluate the efficacy of endoscopic vacuum treatment in patients with primary or secondary gastroesophageal perforations.
Methods
Single-center retrospective cohort study on patients treated for gastroesophageal perforation between March 2019 and September 2022. The inclusion criteria for the study were patients with gastroesophageal perforation resulting from spontaneous rupture or iatrogenic damage (post-surgical or post-endoscopic treatment). The primary outcomes of the study were the success rate of endoscopic therapy, the length of hospital stay, and the specific survival at 30 and 90 days. The success rate of endoscopic therapy was assessed by considering the treatment successful if it led to the resolution of the fistula following vacuum endoscopic therapy. Secondary endpoints included the need for intensive care unit (ICU) stay between the start of vacuum endoscopic therapy and the patient's discharge.
Results
27 patients, with a mean age of 69.8 years (95% CI 65.4-74.3), including 9 (33.3%) women, underwent endoscopic treatment with vacuum therapy for esophageal perforation. The causes of perforation were as follows: 6 (22.2%) cases were primary (Boerhaave syndrome), 15 (55.5%) cases were post-surgical (post-surgical anastomosis), and 6 (22.2%) cases were post-endoscopic treatment (endoscopic dilatation). Among the patients, 13 (48.1%) had previously undergone surgery for cancer, with 69.2% of them receiving intrathoracic stomach interposition reconstruction and the remaining patients undergoing reconstruction according to Roux-en-Y procedure. The treatment was successful in 21 (77.7%) patients, with a 14 days (9.0-24.4, 95% CI) median duration of treatment, and 4 (3-7, 95% CI) median number of endoscopic devices used per patient. One patient (3.7%) died within 30 days, and another one (3.7%) within 90 days. A total of 10 (38.4%) patients required an ICU stay, and there were no readmissions within 30 days. No procedure-related complication was reported. [ 1 ] [ 2 ] [ 3 ]
Conclusions
In the current pilot study, the findings support the feasibility and safety of endoscopic vacuum therapy as a treatment modality for both primary and secondary gastro-esophageal perforations. Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Valente, R., Irino, T., & Arnelo, U. (2024). Endoscopic vacuum therapy for the management of gastro-esophageal perforations. Endoscopy, 56(S 02 S 02), S470. https://doi.org/10.1055/s-0044-1783891
Vancouver
Valente R, Irino T, Arnelo U. Endoscopic vacuum therapy for the management of gastro-esophageal perforations. Endoscopy. 2024;56(S 02 S 02):S470. doi:10.1055/s-0044-1783891
BibTeX
@article{Valente2024,
author = {Valente, R. and Irino, T. and Arnelo, U.},
title = {Endoscopic vacuum therapy for the management of gastro-esophageal perforations},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {S 02 S 02},
pages = {S470},
doi = {10.1055/s-0044-1783891}
}
EUVIMED